Cambridge Healthtech Institute’s Thirteenth Annual Biomarkers and Immuno-Oncology World Congress is our longest-running event dedicated to all areas of biomarker research and development spanning the pharmaceutical and diagnostic pipelines. With the promising developments in immuno-oncology over the past five years, much of the biomarker R&D has shifted to discovery and development of predictive biomarkers for immunotherapy patient stratification, understanding tumor mutational load and neoantigens in developing personalized immunotherapy approaches, using biomarker or mechanism data to choose rational combination immunotherapy, and applying immune profiling to predict response to immunotherapy. In response to the growing interest, we are increasing the coverage of immuno-oncology with four dedicated tracks.
The Biomarkers and Immuno-Oncology World Congress brings together a unique and international mix of large and medium pharmaceutical, biotech, diagnostics companies, leading universities, clinical research institutions, government and national labs, CROs, emerging companies and tool providers. Making the Congress a perfect meeting-place to share experience, foster collaborations across industry and academia, and evaluate emerging technologies.
02May2017 - 04May2017